- Home
- TEF vs BIIB Comparison
TEF vs BIIB Comparison
Compare TEF & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEF
- BIIB
- Stock Information
- Founded
- TEF 1924
- BIIB 1978
- Country
- TEF Spain
- BIIB United States
- Employees
- TEF N/A
- BIIB N/A
- Industry
- TEF Telecommunications Equipment
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- TEF Telecommunications
- BIIB Health Care
- Exchange
- TEF Nasdaq
- BIIB Nasdaq
- Market Cap
- TEF 25.2B
- BIIB 25.1B
- IPO Year
- TEF 1987
- BIIB 1991
- Fundamental
- Price
- TEF $4.45
- BIIB $157.44
- Analyst Decision
- TEF
- BIIB Buy
- Analyst Count
- TEF 0
- BIIB 26
- Target Price
- TEF N/A
- BIIB $255.29
- AVG Volume (30 Days)
- TEF 780.4K
- BIIB 1.5M
- Earning Date
- TEF 11-07-2024
- BIIB 10-30-2024
- Dividend Yield
- TEF 7.14%
- BIIB N/A
- EPS Growth
- TEF N/A
- BIIB 10.05
- EPS
- TEF N/A
- BIIB 11.06
- Revenue
- TEF $45,249,832,683.00
- BIIB $9,607,500,000.00
- Revenue This Year
- TEF $1.62
- BIIB N/A
- Revenue Next Year
- TEF $0.01
- BIIB N/A
- P/E Ratio
- TEF N/A
- BIIB $14.14
- Revenue Growth
- TEF 2.55
- BIIB N/A
- 52 Week Low
- TEF $3.82
- BIIB $153.62
- 52 Week High
- TEF $4.93
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- TEF 49.34
- BIIB 31.68
- Support Level
- TEF $4.45
- BIIB $158.44
- Resistance Level
- TEF $4.60
- BIIB $162.62
- Average True Range (ATR)
- TEF 0.05
- BIIB 3.35
- MACD
- TEF 0.02
- BIIB 0.74
- Stochastic Oscillator
- TEF 55.00
- BIIB 24.34
About TEF Telefonica SA
Telefonica operates mobile and fixed networks in Spain (where it is the incumbent telephone operator), the UK, Germany, Brazil, and other Latin American countries like Colombia, Mexico, Argentina, and Chile. The company derives more than 30% of its revenue from Spain, close to 20% from Germany, and 20% from Brazil. Its UK operations are held through a joint venture with Virgin Media. For several years Telefonica has been simplifying its corporate structure by selling noncore assets.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.